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Background: Treatment of recurrent pterygium associated with symblepharon usually involves 
the use of tissue grafting and/or the intraoperative application of mitomycin C (MMC). For the 
graft, a conjunctival/limbal autograft and/or amniotic membrane may be used. This generally 
requires extra technical skills and assistance, an increase in the cost and duration of surgery, 
and a more extensive anesthesia (a complete eye block or general anesthesia). Although widely 
used, safety concerns have been raised over MMC in the treatment of pterygia.
Objective: The objective of this case report is to report the successful use of preoperative 
subconjunctival injection of low-dose (0.02%) MMC one month before bare sclera excision of 
a multirecurrent pterygium, as well as the concomitant intraoperative application of MMC to 
the conjunctival fornix of the same eye after the excision of an associated symblepharon.
Case report: A 31-year-old man from Kano, Northern Nigeria, presented to the eye clinic 
with a recurrent pterygium associated with an upper lid symblepharon in his right eye. He has 
had five previous pterygium excisions, with the last surgery involving conjunctival autografting 
and subconjunctival steroid injection. He was subsequently given 0.1 mL of 0.02% MMC as a 
subpterygial injection; one month later he had an alcohol-assisted bare sclera pterygium exci-
sion and a symblepharolysis with the intraoperative application of 0.02% MMC for 1 minute 
to the upper conjunctival fornix. Except for a Tenon granuloma that was simply excised, there 
has been no recurrence or other complications up to a year after surgery.
Conclusion: As a cheaper and technically easier treatment option, a preoperative subconjunc-
tival MMC injection followed by bare sclera pterygium excision was found to be effective in 
this patient with a recurrent pterygium. As at one-year follow-up, low-dose preoperative MMC 
a month prior to surgery also appeared safe and effective when combined with its intraoperative 
application to the conjunctival fornix for the treatment of associated symblepharon.
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Introduction
A pterygium is a wing-shaped fibrovascular conjunctival growth that advances onto the 
cornea. It is speculated to occur as a result of a failure of the limbal barrier caused by 
postulated environmental, genetic, and/or various other factors.1 The main challenge 
in the surgical management of pterygia is the issue of recurrence. To prevent this, 
various adjunctive treatments that include chemotherapy, radiotherapy, and surgical 
transplants have been employed.2 Adjuvant treatments have significantly reduced but 
not eliminated the problem; as for the recurrent pterygium, there are greater challenges 
associated with its treatment. Added to an increased recurrence rate is the problem of 
deciding on the best approach to its surgical excision, since a recurrent pterygium is 
usually associated with subconjunctival fibrosis and/or corneal thinning and scarring. 
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There is no recommended best treatment approach for the 
recurrent pterygium. Single treatments or a combination of 
treatments that include tissue grafting and chemotherapeutic 
agents have been utilized with varying degrees of success as 
adjuncts to simple excision.3 The drug Mitomycin C (MMC) 
has vasculopathic and antifibrotic properties and has been 
mainly used after pterygium excision as an intraoperative 
application to the bare sclera for the management of both 
primary and recurrent pterygium.4 In order to further reduce 
recurrence and postoperative complications, an intraoperative 
MMC-treated sclera is normally covered with a conjunctival 
or amniotic membrane graft.5 The possibility of potentially 
serious complications associated with the use of MMC has 
necessitated its usage with caution.2,6 It is therefore not known 
to be used both pre- and intraoperatively on the same patient. 
This report is on the successful such use of low-dose MMC 
in a patient with recurrent pterygium associated with a sym-
blepharon who had undergone five previous excisions.
Case report
A 31-year-old male outdoor salesman presented to the 
ophthalmology department of the Aminu Kano Teaching 
Hospital with a complaint of a recurrent growth on the right 
eyeball. He had had four previous excisions of the growth 
at two different hospitals over the previous five years, but 
with a recurrence less than six months after surgery on 
each occasion. The nature of the previous surgeries was not 
clear, but there was nothing suggestive of adjuvant use of 
chemo or radiotherapy. There was no history suggestive of 
systemic illness, blepharitis, allergy, or dry eye disease. On 
examination, he had a visual acuity of 6/9 OD and 6/6 OS 
that improved with refraction by one line for each eye. The 
eyelids were normal and there was a fleshy recurrent nasal 
pterygium on the right eye that extended to the edge of the 
pupil. Ophthalmoscopy revealed a normal fundus and there 
was no restriction of extraocular muscle motility. Using 
topical 0.5% tetracaine hydrochloride (Alcon-Couvreur, 
Puurs, Belgium) and subconjunctival 2% lignocaine with 
1:100,000 noradrenaline (Lignovit 20-AH, Vital Health-
care PVT Limited, Mumbai, India) local anesthesia, he 
subsequently underwent a simple pterygium excision (avul-
sion technique) followed by a free conjunctival autograft 
that was harvested from the superior bulbar conjunctiva 
and secured with 9/0 nylon suture. He was then given a 
subconjunctival injection of 20 mg methylprednisolone 
acetate (Depomedrol, Pfizer Limited, Mumbai, India) in 
the lower fornix. Histology confirmed a pterygium and, 
postoperatively, he was placed on 6-hourly topical 0.1% 
dexamethasone eye drops (Maxidex, Alcon-Couvreur, 
Puurs, Belgium) and 8-hourly 0.5% chloramphenicol eye 
drops (Elisca, Medreich, Bangalore, India) for four weeks 
and 50-mg oral diclofenac tablets (Clofenac, Hovid Berhad, 
Malaysia) twice daily for one week. Four months after this 
fifth excision, and while still on his now-12-hourly steroid 
eye drops, there was a pterygium recurrence that kept grow-
ing across the limbus and onto the cornea. This was later 
complicated by the formation of an upper lid symblepharon 
(Figure 1).
Three months after this fifth reoccurrence, the patient 
had a preoperative subpterygial injection of 0.1 mL of 
0.02% MMC (MMC Kyowa, Biochem Industries, Daman, 
India) in preparation for the sixth surgical procedure. 
A month after the MMC injection and under local anesthesia 
as in the fifth procedure, he underwent an excision of the 
symblepharon, including the surrounding subconjunctival 
fibrous tissue. MMC (0.02%) was applied using a sponge 
to the deep upper conjunctival fornix for 1 minute, followed 
by copious saline irrigation. An ethanol (20%)-assisted 
blunt pterygium excision was then done, leaving a bare 
untreated sclera. Postoperative medication was prescribed 
as in after the fifth excision. There were no intraoperative 
  complications, and postoperative cosmesis was good after 
this sixth procedure. Two months later, the patient devel-
oped a small Tenon’s granuloma that was simply excised 
and histologically confirmed. There have been no other 
complications or recurrence of pterygium since then, up to 
a year after the sixth procedure (Figure 2). There has been 
full extraocular muscle motility, and unaided visual acuity 
has remained unchanged.
Figure 1 Multirecurrent pterygium (five previous excisions) with symblepharon 
before treatment.
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Discussion
Conjunctival or limbal autografts and amniotic membrane 
transplants have been commonly used alone or combined 
with MMC as adjuvant treatment for recurrent pterygium3 
with fairly good results, whether there was an associated 
symblepharon or not. Perhaps the recently described method 
of extended pterygium removal followed by an extended 
and relatively large conjunctival graft seems to be the most 
promising treatment that tends toward a zero-recurrence 
rate.7 This should probably be the recommended treatment 
of choice for recurrent pterygia, even though it has some 
drawbacks. These drawbacks include the requirement for 
a more extensive or general anesthesia, a longer operat-
ing time of about 2 hours, the need for a skilled assistant, 
poor immediate postoperative cosmesis, and a relatively 
prolonged postoperative diplopia and pain. MMC in the 
treatment of recurrent pterygia has been more commonly 
used as an intraoperative topical application.2,8 Preoperative 
subconjunctival injections of MMC are usually given from a 
day up to a month prior to surgery, and intraoperative tissue 
grafting to cover the bare sclera after pterygium excision is 
usually not necessary.9 This mode of use makes it technically 
easier compared to other methods that involve tissue graft-
ing and, in comparison to intraoperative MMC, allows for 
exact dose titration to the intended site, thereby increasing 
its effectiveness in preventing pterygium recurrence. This 
may, however, increase the risk for complications, as was 
reported by Carrasco et al,10 where a 55-year-old man with 
preexisting dry eye disease developed scleral ulceration 
after a preoperative injection of 0.15 mL of low-dose MMC. 
Adjuvant MMC treatment in all cases must of course only 
be used in patients with no contraindications to its use, such 
as dry eye disease and conditions that predispose to poor 
wound healing. When there is an associated symblepharon, 
preoperative subpterygial MMC and the later intraoperative 
use of MMC to the conjunctival fornix may carry fewer wor-
ries about toxicity compared to simultaneous intraoperative 
application of MMC to the sclera and fornix. In this patient, 
the same low-dose MMC was applied to the deep upper con-
junctival fornix for 1 minute before saline irrigation. A higher 
MMC dose (up to 0.04%) or longer application period 
(commonly 3 to 5 minutes ) was not used for this patient 
in order to reduce the risk of postoperative   MMC-related 
complications. Costs and surgical time are reduced when 
items like amniotic membrane and suture/tissue glue are 
not used. The added cost and non-availability of these items 
at the time of surgery was the main reason for the choice of 
using preoperative MMC over other options in this patient. 
Although subconjunctival/subpterygial injections could be 
slightly more difficult to give for recurrent pterygia (due to 
subconjunctival scarring and fibrosis), that is less of a task 
compared to harvesting conjunctiva for grafting on an eye 
that had possibly undergone a previous graft, as is the case 
with this patient. Some surgeons prefer preoperative MMC a 
week or even a day prior to surgery. Timing differences may 
not be important, but shorter times may presumably lead 
to a higher incidence of postoperative complications such 
as delayed corneal epithelial healing and scleral thinning/
avascularity. This is, however, subject to confirmation by 
large-sample comparative studies. However, in a study by 
Zaky and Khalifa11 where subconjunctival low-dose MMC 
was given a day prior to surgery, out of a total of 25 eyes 
with recurrent pterygia, two had postoperative delayed 
epithelization. For this patient, prior MMC injection a 
month instead of a day or few days prior to surgery was pre-
ferred because of the intended intraoperative MMC fornix 
application. Other possible but relatively minor complications 
associated with the use of MMC include superficial punctuate 
keratitis, corneal edema, scleritis, scleral dellen, and pyogenic 
  granuloma.12 In view of its radiomimetic properties, MMC 
also has the potential for long-term complications that could 
include uveitis, cataract, glaucoma, endophthalmitis, and 
scleral melting leading to globe perforation.2,13 Therefore, 
there is a need for long-term follow-up of the patient dis-
cussed in this case report.
Conclusion
This case would generally seem to suggest that, in some 
selected patients with recurrent pterygium associated 
Figure 2 A year after bare sclera excision with adjunctive pre and intraoperative 
use of mitomycin C.
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with a symblepharon, the combined use of preoperative 
  subconjunctival low dose MMC injections up to a month 
prior to pterygium excision, along with its intraoperative 
conjunctival fornix application after symblepharolysis, could 
serve as an effective and technically easier adjuvant treatment 
option. Larger cohort studies and postoperative monitoring 
over much longer time periods will, however, be needed in 
order to fully evaluate treatment safety profile.
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